thrombopoietin receptor agonists
Treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a procedure.
Acts as a thrombopoietin receptor agonist which increases platelet production by initiating proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.
Distribution: Well distributed to tissues.
Protein Binding: >99%.
Metabolism and Excretion: Primarily metabolized in liver via CYP4 isoenzymes. Primarily excreted in feces (83%) with 16% being eliminated as unchanged drug.
Half-life: 27 hr.
TIME/ACTION PROFILE (plasma concentrations)
|PO||unknown||6–8 hr||24 hr|
Use Cautiously in:
GI: PORTAL VEIN THROMBOSIS
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Should not be used in patients with chronic liver disease to normalize platelet counts.
PO (Adults): 3 mg once daily for 7 days. Begin therapy 8–14 days prior to the scheduled procedure such that the procedure takes place 2–8 days after the final dose.
Tablets: 3 mg
Lab Test Considerations:
Obtain platelet count before starting therapy and not >2 days before procedure.
Emergency Central is a collection of disease, drug, and test information including 5-Minute Emergency Medicine Consult, Davis’s Drug, McGraw-Hill Medical’s Diagnosaurus®, Pocket Guide to Diagnostic Tests, and MEDLINE Journals created for emergency medicine professionals. Complete Product Information.